Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, Rutherford M, Sethi H, Boydell A, Swenerton R, Fernandez-Garcia D, Gleason KLT, Goddard K, Guttery DS, Assaf ZJ, Wu HT, Natarajan P, Moore DA, Primrose L, Dashner S, Tin AS, Balcioglu M, Srinivasan R, Shchegrova SV, Olson A, Hafez D, Billings P, Aleshin A, Rehman F, Toghill BJ, Hills A, Louie MC, Lin CJ, Zimmermann BG, Shaw JA. Coombes RC, et al. Among authors: rehman f. Clin Cancer Res. 2019 Jul 15;25(14):4255-4263. doi: 10.1158/1078-0432.CCR-18-3663. Epub 2019 Apr 16. Clin Cancer Res. 2019. PMID: 30992300
Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
Nteliopoulos G, Page K, Hills A, Howarth K, Emmett W, Green E, Martinson LJ, Fernadez-Garcia D, Hastings R, Guttery DS, Kenny L, Stebbing J, Cleator S, Rehman F, Gleason KLT, Sanela A, Ion C, Rushton AJ, Rosenfeld N, Coombes RC, Shaw JA. Nteliopoulos G, et al. Among authors: rehman f. Breast Cancer Res Treat. 2021 Jul;188(2):465-476. doi: 10.1007/s10549-021-06220-9. Epub 2021 Jun 7. Breast Cancer Res Treat. 2021. PMID: 34097174 Free PMC article.
A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer.
Lerner A, Keshwani K, Okines A, Sanderson B, Board RE, Flynn M, Sharkey E, Konstantis A, Roylance R, Hanna D, King J, Murphy R, Rehman F, Guppy AE, Westbury C, Takeuchi E, Spurrell E, Jayaweera HK, Raja F. Lerner A, et al. Among authors: rehman f. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):261-266. doi: 10.1016/j.clon.2021.12.012. Epub 2022 Jan 10. Clin Oncol (R Coll Radiol). 2022. PMID: 35027287
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Battisti NML, Kingston B, King J, Denton A, Waters S, Sita-Lumsden A, Rehman F, Stavraka C, Kristeleit H, Sawyer E, Houghton D, Davidson N, Howell S, Choy J, Harper P, Roylance R, Fharat R, Mohammed K, Ring A, Johnston S. Battisti NML, et al. Among authors: rehman f. Breast Cancer Res Treat. 2019 Apr;174(3):731-740. doi: 10.1007/s10549-019-05134-x. Epub 2019 Jan 17. Breast Cancer Res Treat. 2019. PMID: 30656459
Synthetic lethal approaches to breast cancer therapy.
Rehman FL, Lord CJ, Ashworth A. Rehman FL, et al. Nat Rev Clin Oncol. 2010 Dec;7(12):718-24. doi: 10.1038/nrclinonc.2010.172. Epub 2010 Oct 19. Nat Rev Clin Oncol. 2010. PMID: 20956981 Review.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Bajrami I, et al. Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15. Cancer Res. 2014. PMID: 24240700 Free PMC article.
347 results